Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Open J Immunol. 2018 Jun 29;8(2):36–80. doi: 10.4236/oji.2018.82004

Figure 8.

Figure 8.

Irinotecan chemotherapy can eliminate the wild-type and mutant cancer cells if there are no pro-tumor polarized immune cells at the start of treatment, despite a weak CTL response. The cytokine plot shows that the concentration of pro-tumor cytokines IL-4, IL-10 and IFN-α released by M2 macrophages and Th2 helper cells decrease over time, leading to the success of Irinotecan chemotherapy.